Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 3
2022 7
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Antitumor Peptide-Based Vaccine in the Limelight.
Kumai T, Yamaki H, Kono M, Hayashi R, Wakisaka R, Komatsuda H. Kumai T, et al. Among authors: wakisaka r. Vaccines (Basel). 2022 Jan 3;10(1):70. doi: 10.3390/vaccines10010070. Vaccines (Basel). 2022. PMID: 35062731 Free PMC article. Review.
Harnessing Immunity to Treat Advanced Thyroid Cancer.
Komatsuda H, Kono M, Wakisaka R, Sato R, Inoue T, Kumai T, Takahara M. Komatsuda H, et al. Among authors: wakisaka r. Vaccines (Basel). 2023 Dec 30;12(1):45. doi: 10.3390/vaccines12010045. Vaccines (Basel). 2023. PMID: 38250858 Free PMC article. Review.
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.
Nagato T, Komatsuda H, Hayashi R, Takahara M, Kishibe K, Yasuda S, Yajima Y, Kosaka A, Ohkuri T, Oikawa K, Harabuchi S, Kono M, Yamaki H, Wakisaka R, Hirata-Nozaki Y, Ohara K, Kumai T, Katada A, Hayashi T, Harabuchi Y, Kobayashi H. Nagato T, et al. Among authors: wakisaka r. Cancer Immunol Immunother. 2023 Jul;72(7):2087-2098. doi: 10.1007/s00262-023-03394-7. Epub 2023 Feb 22. Cancer Immunol Immunother. 2023. PMID: 36811663
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
Yamaki H, Kono M, Wakisaka R, Komatsuda H, Kumai T, Hayashi R, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Hayashi T, Kobayashi H, Katada A. Yamaki H, et al. Among authors: wakisaka r. Cancer Immunol Immunother. 2023 Aug;72(8):2799-2812. doi: 10.1007/s00262-023-03460-0. Epub 2023 May 12. Cancer Immunol Immunother. 2023. PMID: 37173455
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Kobayashi H, Harabuchi Y. Kono M, et al. Among authors: wakisaka r. Oncoimmunology. 2022 Jan 3;11(1):2021619. doi: 10.1080/2162402X.2021.2021619. eCollection 2022. Oncoimmunology. 2022. PMID: 35003900 Free PMC article.
Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation.
Komatsuda H, Wakisaka R, Kono M, Kumai T, Hayashi R, Yamaki H, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Takahara M, Katada A, Kobayashi H. Komatsuda H, et al. Among authors: wakisaka r. Cancer Sci. 2023 Feb;114(2):399-409. doi: 10.1111/cas.15619. Epub 2022 Nov 28. Cancer Sci. 2023. PMID: 36285482 Free PMC article.
16 results